HUMA vs NVCR vs JPM vs HOLX vs MDT

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Humacyte, Inc. (HUMA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 2x versus Hologic, Inc. at 30. 5x. On forward P/E, Medtronic plc is actually cheaper at 13. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus Medtronic plc's 33. 92x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -93. 5% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: JPM returned +481. 2% versus HUMA's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 12β versus Humacyte, Inc. 's 3. 26β — meaning HUMA is approximately 2723% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 21% for Humacyte, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Humacyte, Inc. grew EPS 79. 4% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, HUMA leads at 9. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -20. 0% for Humacyte, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -52. 7% for HUMA. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus Medtronic plc's 33. 92x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 13. 3x forward P/E versus 17. 2x for Hologic, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HUMA: 503. 6% to $5. 58.

In this comparison, MDT (3.

5% yield), JPM (1. 8% yield) pay a dividend. HUMA, NVCR, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

31), 3. 5% yield). Humacyte, Inc. (HUMA) carries a higher beta of 3. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +22. 0%, HUMA: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HUMA (Healthcare) and NVCR (Healthcare) and JPM (Financial Services) and HOLX (Healthcare) and MDT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HUMA is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; HOLX is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock. JPM, MDT pay a dividend while HUMA, NVCR, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.